The Triptan Family

## Overview

Triptans revolutionized migraine treatment when sumatriptan was introduced in 1991. They are selective agonists of 5-hydroxytryptamine 1B (5-HT1B) and 5-HT1D receptor subtypes, aborting migraine attacks through two complementary mechanisms: cranial vasoconstriction (via 5-HT1B on meningeal and basilar arteries, reversing the vasodilation that precedes migraine) and inhibition of trigeminal nerve firing and neuropeptide (CGRP, substance P) release (via 5-HT1D on trigeminal neurons and their central projections).

## Tryptamine Pharmacophore

The tryptamine scaffold (indole + 2-carbon aminoethyl side chain at C3) is the minimal pharmacophore for serotonin receptor agonism. Natural serotonin itself is 5-hydroxytryptamine. Triptans replace the 5-hydroxyl with sulfonamide, methyl, methoxy, or heterocyclic substituents at C5, which simultaneously alters receptor subtype selectivity (away from 5-HT2 and 5-HT3, toward 5-HT1B/1D) and controls physicochemical properties.

## Receptor Selectivity

The 5-HT1B receptor mediates vasoconstriction of cranial vessels; coronary vasospasm is an off-target concern since coronary arteries also express 5-HT1B. The sulfonamide group in sumatriptan dramatically reduces lipophilicity (logD pH 7.4 ≈ -1.4), which simultaneously limits CNS penetration and is thought to limit cardiac exposure (though coronary vasospasm remains a contraindication in ischemic heart disease patients for all triptans). Later triptans (rizatriptan, zolmitriptan, eletriptan) deliberately increased lipophilicity and CNS penetration to engage both peripheral 5-HT1B and central 5-HT1D pathways.

## Structural Evolution

**Sumatriptan** established the proof of concept. Its drawbacks—low oral bioavailability (~14%), short half-life (~2 h), subcutaneous/nasal/oral formulations needed—drove the development of second-generation triptans. **Naratriptan** replaced the dimethylaminoethyl with a methylpiperidine ring, improving bioavailability (~68%) and extending half-life (~5 h) at the cost of slower onset. **Rizatriptan** introduced a triazole-methyl group at C5 and the triazole ring, achieving the fastest oral onset in the class (~30 min). **Frovatriptan** used a fused carbazole-like pyrroloindole scaffold that confers exceptional 5-HT1B/1D selectivity and the longest half-life (~26 h), making it preferred for menstrual migraine prophylaxis.

## Oral Bioavailability Challenges

Low first-pass hepatic metabolism is a challenge for aminoethylindoles. Sumatriptan's poor bioavailability prompted the development of nasal and subcutaneous formulations. Zolmitriptan's oxazolyl prodrug design partially addresses this. Eletriptan, with its N-methyl group, has better CYP3A4 stability. The Janus-faced nature of MAO-A (which deaminates the ethylamine) means triptans are contraindicated with MAO inhibitors to prevent serotonin toxicity.

## CGRP Antagonists: Successor Paradigm

The newer anti-migraine class, gepants (rimegepant, ubrogepant) and CGRP-blocking monoclonal antibodies (erenumab, fremanezumab), directly target the CGRP pathway activated during trigeminal neuron firing. They do not cause vasoconstriction and lack the cardiovascular contraindications of triptans. They represent a mechanistically distinct approach made possible by understanding the downstream consequences of 5-HT1D activation that triptans indirectly modulate.

## Key Takeaways

- The tryptamine pharmacophore (indole + 2C-aminoethyl) defines all triptans; C5 substitution governs 5-HT1B/1D selectivity
- Sulfonamide (sumatriptan) limits lipophilicity and CNS penetration; lipophilic substituents increase CNS entry for central efficacy
- Cyclic amines (naratriptan's piperidine) and N-methyl (eletriptan) improve oral bioavailability and metabolic stability
- Frovatriptan's rigid bicyclic scaffold achieves the highest selectivity and longest half-life, useful for menstrual migraine prophylaxis
- CGRP-targeted therapies have largely superseded triptans in prevention, but triptans remain first-line acute treatment